Menu
simplePharmaceuticalInnovation IndexInnovation Index

Pharmaceutical Digital Health Innovation Index, 5th Edition

Digital health is no longer a side experiment—it’s reshaping how pharma discovers, develops, and delivers therapies. As companies race to build evidence-driven partnerships and real digital impact, the gap between leaders and followers is widening. Galen Growth’s 5th annual Pharmaceutical Digital Health Innovation Index reveals who is truly executing, who isn’t, and what it takes to stay ahead in an industry transforming at unprecedented speed—right now globally today.

Pharma Innovation Index 2025_00

Who’s Really Shaping the Digital Future of Pharma in 2025?

For a decade, Galen Growth has tracked digital health’s rise from experiments to a strategic pillar. This fifth edition of the Pharmaceutical Digital Health Innovation Index—released during Galen Growth’s 10th anniversary—evaluates the top 25 pharma companies using evidence-based signals, not perception or PR. It reveals how external digital innovation is reshaping value chains and where true impact is emerging. For investors, the Index offers rare visibility into ventures gaining traction through repeat partnerships, clinical evidence, and real-world integration. For pharma leaders, it highlights who is embedding digital health into R&D, trials, and DTP models—and who is struggling to scale. For innovators, it clarifies what pharma truly values: strategic fit, evidence, and the ability to move beyond pilots.

Powered by HealthTech Alpha’s billion-plus data points, this Index provides a clear, rigorous blueprint for capital allocation, partnerships, and transformation.

Key Insights from the Report

  • More pharma companies are embracing digital health. In 2021, the top 25 pharma companies held 57% of global digital health partnerships in the sector. By the end of 2025, this share has dropped to 42%, highlighting increased adoption by the broader ecosystem.
  • As the ecosystem grows more complex and diversified, pharma’s share of partnerships is naturally shifting, reaching only 13% in 2025 —reflecting the rise of new entrants and innovative models that are expanding the boundaries of digital health.
  • In the past 2 years, 7 pharma companies have built direct-to-patient (DTP) platforms in the US, with others offering single drugs DTP. With the Trump Rx platform possibly threatening the DTP business model, 2026 will be a pivotal year for the future of such platforms.

Ventures and Companies Covered in the Report

docdok.health, Huma, BrightInsight, Sidekick Health, Jenevive Health, SmartPatient, Gencurix (젠큐릭스), Beacon Biosignals, Owkin, Theranica, AstraZeneca, Novartis, Servier, UCB Pharma, Eli Lilly, Merck KGaA, Pfizer, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Merck KGaA, Roche, MSD/Merck & Co., Astellas Pharma, Takeda, GSK, Johnson & Johnson Innovative Medicine, Gilead Sciences, Abbvie, Otsuka Precision Health, Daiichi Sankyo, Bayer, Biogen, Amgen

About the Data

The report is powered by HealthTech Alpha, the premier digital health intelligence platform delivering unparalleled data and insights into the evolving healthcare technology landscape. Leveraging an extensive database of over 16,000 ventures and cutting-edge analytics, HealthTech Alpha provides a data-driven foundation to analyse the critical trends shaping the future of digital health.

Designed to empower stakeholders—including investors, pharmaceutical leaders, and medical device manufacturers—HealthTech Alpha offers actionable intelligence to navigate digital transformation complexities. This collaboration ensures readers gain a comprehensive, evidence-based view of the intersection between digital health and healthcare, equipping them to identify strategic opportunities, assess market dynamics, and stay ahead in this fast-evolving industry.

Get the report

Use your company email address. Personal and disposable email services are not accepted.